Anti-HER3 antibodies have been developed for therapeutic use [14,15], with some anti-HER3 antibodies being reported to abrogate resistance against agents targeting the EGFR family in CRC and breast cancer cells [16,17]. Here, ERBB3 is linked to breast carcinoma.